Terapia ormonale de-escalation con rischio stratificato con radioterapia per il trattamento del cancro alla prostata
Trattamento deintensificato e ridotto del rischio stratificato per i pazienti con cancro alla prostata ad alto rischio basato su criteri patologici, punteggio genetico e imaging biologico
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Research has shown that long-term ADT is beneficial for patients with high-risk prostate cancer. However, there are few studies that determine ADT treatment based on risk factors. Giving risk based de-escalated ADT with radiation therapy may be as effective as giving more ADT in treating high-risk prostate cancer.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
PRIMARY OBJECTIVE:
I. Recovery of the Expanded Prostate Cancer Index Composite (EPIC) hormonal domain to baseline levels at 2-years.
EXPLORATORY OBJECTIVES:
I. After completion of radiation therapy, determine the incidence of:
Ia. Grade 2 or greater genitourinary (GU) and gastrointestinal (GI) toxicity at 6 months (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0); Ib. Grade 3 or greater GU and GI toxicity at 6 months (CTCAE version 5.0); Ic. Patient-reported quality of life; Id. Impotence after the use of radiation therapy at 3 years; Ie. Freedom from biochemical failure (FFBF) at 5 years; If. Clinical failure: local and/or distant at 5 years; Ig. Salvage androgen deprivation use (SAD) at 5 years; Ih. Progression free survival: using clinical, biochemical and SAD as events at 5 years; Ij. Overall survival at 5 years; Ik. Disease-specific survival at 5 years. II. Determine overall GI and GU toxicity.
OUTLINE: Patients are assigned to 1 of 3 risk groups.
GROUP I (LOW RISK): Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks.
GROUP II (INTERMEDIATE RISK): Patients receive ADT subcutaneously (SC) or intramuscularly (IM) for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy.
GROUP III: (HIGH RISK): Patients receive ADT SC or IM with or without abiraterone acetate for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to identified areas over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy.
Additionally, patients undergo positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI), and blood sample collection throughout the trial.
After completion of study treatment, patients are followed up at months 3 and 12, then yearly for up to year 5 followed by every 2 years.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259
- Mayo Clinic in Arizona
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically confirmed high risk prostate adenocarcinoma
- Pathologic stages T1c-T4, N0-Nx-N1, M0-1 as staged by the pathology report (AJCC Criteria 8th Edition [Ed].)
- One or more high risk features including Gleason 8-10, T3-T4, prostate specific antigen (PSA) ≥ 20
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients must sign institutional review board (IRB) approved study specific informed consent
- Patients must complete all required pre-entry tests
- Patients must be at least 18 years old
- Oligometastatic prostate cancer defined as disease in up to 5 distant or regional areas (group 3 only)
Exclusion Criteria:
- Previous pelvic radiation
- Prior androgen suppression therapy for prostate cancer for more than 6 months
- Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)
- Prior systemic chemotherapy for prostate cancer
- History of proximal urethral stricture requiring dilatation
- Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low-molecular weight heparin, clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or place markers)
- Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study)
- Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed)
- History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group I (radiation therapy)
Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo radiation therapy
Altri nomi:
|
|
Sperimentale: Group II (ADT, radiation therapy)
Patients receive ADT SC or IM for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo radiation therapy
Altri nomi:
Given SC or IM
Altri nomi:
|
|
Sperimentale: Group III (ADT, radiation therapy, abiraterone acetate)
Patients receive ADT SC or IM with or without abiraterone acetate for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to identified areas over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Altri nomi:
Undergo CT
Altri nomi:
Undergo MRI
Altri nomi:
Ancillary studies Undergo PET
Altri nomi:
Undergo radiation therapy
Altri nomi:
Given SC or IM
Altri nomi:
Given abiraterone acetate
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hormonal domain scores
Lasso di tempo: At baseline and up to 2 years
|
Measured by the Expanded Prostate Cancer Index Composite. Comparison will be made using a one-sided, paired-difference t-test, with a Type I error rate of 0.025. |
At baseline and up to 2 years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Carlos E. Vargas, M.D., Mayo Clinic
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Ormoni
- Ormoni, sostituti ormonali e antagonisti ormonali
- Ormoni a rilascio di ormoni ipofisari
- Ormoni ipotalamici
- Ormoni peptidici
- Neuropeptidi
- Peptidi
- Aminoacidi, peptidi e proteine
- Oligopeptidi
- Proteine del tessuto nervoso
- Proteine
- Tecniche investigative
- Terapie
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Fenomeni fisici
- Composti policiclici
- Steroidi
- Composti anelli fusi
- Tecniche di chimica, analitiche
- Analisi dello spettro
- Androstenes
- Androstanes
- Acetato di Abiraterone
- Ormone a rilascio di gonadotropina
- Radioterapia
- Radiazione
- Gestione dei campioni
- Spettroscopia di risonanza magnetica
Altri numeri di identificazione dello studio
- GMROA2256
- GMROA2256 (Altro identificatore: Mayo Clinic in Arizona)
- NCI-2024-03020 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
- 22-012591 (Altro identificatore: Mayo Clinic Institutional Review Board)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .